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Abstract
Viral binding and entry provides the first trigger of a cell death response and thus how human 
cytomegalovirus (HCMV) evades this – particularly during latent infection where a very limited 
pattern of gene expression is observed – is less well understood. It has been demonstrated that the 
activation of cellular signalling pathways upon virus binding promotes the survival of latently 
infected cells by the activation of cell encoded anti-apoptotic responses. In CD34+ cells, a major 
site of HCMV latency, ERK signalling is important for survival and we now show that the 
activation of this pathway impacts on multiple aspects of cell death pathways. The data illustrate 
that HCMV infection triggers activation of pro-apoptotic Bak which is then countered through 
multiple ERK-dependent functions. Specifically, ERK promotes ELK1 mediated transcription of 
the key survival molecule MCL-1, along with a concomitant decrease of the pro-apoptotic BIM 
and PUMA proteins. Finally, we show that the elimination of ELK-1 from CD34+ cells results in 
elevated Bak activation in response to viral infection, resulting in cell death. Taken together, these 
data begin to shed light on the poly-functional response elicited by HCMV via ERK-MAPK to 
promote cell survival.
Introduction
Amongst the first host responses activated upon viral infection are cell autonomous immune 
responses. These functions are ubiquitous to every cell type and are normally triggered by 
pattern recognition receptors which detect various components of the incoming pathogen 
(Bieniasz 2004; Everett & Chelbi-Alix 2007; Randow et al. 2013). One aspect of the cell 
autonomous immune response is the activation of apoptotic and cell death pathways, which 
will ultimately eliminate both the pathogen and the infected cell (Clem et al. 1991; Everett 
& McFadden 1999; Levine et al. 1993). During lytic infection, human cytomegalovirus 
(HCMV) counters this with an arsenal of virally encoded anti-apoptotic functions that 
counter stress signals induced by viral binding and, subsequently, throughout the course of 
Correspondence should be addressed to Matthew Reeves; Tel: +44 207 794 0500 ext 33109, Fax: +44 207 830 2854, 
matthew.reeves@ucl.ac.uk. 
Conflicts of interest
The authors declare no conflicts of interest associated with this work.
Authors’ contributions
VGK, MRW and MBR performed experiments and MRW and MBR analysed the data and wrote the paper.
Europe PMC Funders Group
Author Manuscript
J Mol Biochem. Author manuscript; available in PMC 2017 May 08.
Published in final edited form as:
J Mol Biochem. 2017 ; 6(1): 13–25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
viral replication (Brune 2010; Goldmacher et al. 1999; Guo et al. 2015; Reeves et al. 2007; 
Skaletskaya et al. 2001; Stevenson et al. 2014; Terhune et al. 2007). However, a lack of 
expression of these functions in non-lytic infections raised the question of how cell survival 
is achieved – particularly during the initial phases of infection.
Current studies hypothesise that viral infection in cells non-permissive for lytic infection 
requires the generation of a pro-survival phenotype driven by virally induced up-regulation 
of key cellular anti-apoptotic proteins (Chan et al. 2010; Peppenelli et al. 2016; Reeves et al. 
2012; Stevenson et al. 2014). This event relies on the regulation of a number of prosurvival 
and pro-death signals via the modulation of cellular signalling pathways initiated upon virus 
binding and entry (Chan et al. 2010; Reeves et al. 2012). It is the outcome of these signalling 
events which, ultimately, determines the fate of the cell during these very early stages of 
infection. Once latency is established, there are additional mechanisms activated which 
would be consistent with the latent virus propagating an anti-apoptotic state (Poole et al. 
2011, 2015; Slobedman et al. 2004).
Apoptosis and cell death is an evolutionarily conserved process that is extensively regulated 
by Bcl-2 homology domain 3 (BH3) proteins (Doerflinger et al. 2015; Horvitz 1999; 
Puthalakath & Strasser 2002). The precise mechanism of action still remains equivocal 
although it is clear that the BH3 proteins trigger the activation of key apoptosis effector 
proteins (e.g. Bak and Bax) which exert their pro-apoptotic function predominantly at 
mitochondrial membranes (Wei et al. 2001; Westphal et al. 2014). A number of regulatory 
mechanisms have been suggested: The indirect activation model posits that Bax/Bak are 
required to be retained in an inactive form via direct sequestration by anti-apoptotic BCL-2 
family members (Willis et al. 2005) and that BH3 proteins must engage with these to release 
the Bax/Bak to initiate apoptosis (Uren et al. 2007; Willis et al. 2007). The direct activation 
model hypothesises that BH3-only activators (e.g. PUMA and BIM) bind to Bak/Bax 
directly to activate them or, alternatively, other BH3 members (e.g. Bad) target BCL-2 
members and inhibit their anti-apoptotic function through sequestration (Doerflinger et al. 
2015; Erlacher et al. 2006; Kuwana et al. 2002; Villunger et al. 2003; Wei et al. 2000). The 
most recent evidence argues that these events are not mutually exclusive and that, instead, 
both mechanisms of regulation are likely to be active (Llambi et al. 2011; Westphal et al. 
2014) although the strict delineation between activators and sensitisers in the BH3 family 
may not be entirely valid (Westphal et al. 2014).
Our own research interests have centred on the BCL-2-like protein myeloid cell leukaemia-1 
(MCL-1). Unlike other BCL-2 proteins the regulation of MCL-1 is dynamic with a turnover 
of 30 minutes under certain experimental conditions (Adams & Cooper 2007; Warr & Shore 
2008) and it is thus considered a highly responsive determinant of haematopoietic cell 
viability (Perciavalle & Opferman 2013) – the ablation of this protein from progenitor cells 
of the haematopoietic lineage being lethal (Opferman et al. 2005; Perciavalle & Opferman 
2013). MCL-1 (along with BCL-XL) has been suggested to block Bak activity to exert an 
anti-apoptotic function (Willis et al. 2005) and is regulated by both the PI3K and ERK-
MAPK pathways (Huang et al. 2000; Mills et al. 2008). Pertinently, MCL-1 is also regulated 
by HCMV through activation of the ERK and PI3K pathways in a cell type specific manner 
(Chan et al. 2010; Reeves et al. 2012). Depletion of MCL-1 from monocytes or THP1 cells 
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renders them unable to prevent virally induced cell death upon infection (Chan et al. 2010; 
Reeves et al. 2012). In CD34+ cells, HCMV survival is also associated with MCL-1 (Reeves 
et al. 2012) although the absolute requirement for endogenous MCL-1 in normal CD34+ 
cells rendered similar genetic analysis through MCL-1 deletion intractable. The inducible 
survival effect in CD34+ cells required virus binding and was likely dependent on the 
engagement of glycoprotein B with an unknown receptor. Furthermore, the survival effect 
induced was transient (Reeves et al. 2012) and thus did not appear to be propagated for as 
long as was observed in the monocyte model of infection (Chan et al. 2010).
ELK-1 is part of a 27 member superfamily of transcription factors that dictate a diverse 
range of processes including haematopoiesis, differentiation and survival, oncogenesis and 
inflammation (Sharrocks 2001). ELK-1 is a nuclear phosphoprotein that exhibits bimodal 
activity: redundant promoter binding via dimers with other Ets transcription factors and 
specific binding to a subset of genes through an interaction with serum response factor 
(SRF) (Odrowaz & Sharrocks 2012; Sharrocks 2001). Amongst these genes are MCL-1 and 
c-Fos, which, characteristically for this subset of genes, are dynamically regulated (Boros et 
al. 2009; Treisman et al. 1992). The activation of ELK-1 requires phosphorylation of serine 
residue 383 promoting the recruitment of transactivating co-factors to promoters in order to 
drive transcription (Boros et al. 2009; Gille et al. 1992, 1995). Furthermore, ELK-1 
mediated activation of MCL-1 gene expression has been shown to be important for survival 
in a number of experimental models (Booy et al. 2011; Demir et al. 2011; Sun et al. 2013; 
Townsend et al. 1999) and likely contributes to the role of ELK-1 in cancer.
Herein we wanted to further explore the consequences of HCMV infection on the 
development of an anti-apoptotic phenotype in CD34+ cells based on our previous studies of 
MCL-1 and ERK-MAPK signalling. Here we show that the HCMV protection from cell 
death is concomitant with an inhibition of prolonged Bak activation in response to chemical 
and viral insult. Secondly, we show that the protective phenotype driven by virus induced 
ERK-MAPK signalling correlates with the down-regulation of pro-apoptotic BH3 proteins 
PUMA and BIM and, concomitantly, is dependent on the phosphorylation and thus 
activation of ELK-1 – a transcription factor important for MCL-1 expression and cell 
survival. Importantly, knock down of ELK-1 expression is sufficient to abrogate the 
protective effect elicited by HCMV infection. Taken together, these data suggest that HCMV 
infection drives a survival phenotype by simultaneously up-regulating MCL-1 proteins levels 
and reducing the levels of antagonistic interaction partners. We propose that the net effect 
tips the balance in favour of survival contributing to the successful establishment of latent 
infection.
Materials and Methods
Virus, cell lines, culture and reagents
The Merlin strain of HCMV was purified from infected human fibroblasts as previously 
described (Compton 2000). Primary CD34+ haematopoietic cells (Lonza, Slough, UK) were 
resuscitated for 24 hours prior to any studies of cell viability in X-vivo-15 (Biowhittaker, 
Lonza, Slough, UK) media supplemented with 10% human serum. For all subsequent 
studies, cells were switched into serum-free X-vivo media supplemented with 2mM L-
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Glutamine. For all infection experiments an MOI of 5 (based on titration in fibroblasts) was 
used.
Inhibition of the ERK-MAPK pathway was achieved using U0126 (final concentration 1uM; 
Calbiochem/Millipore, Darmstadt, Germany). The inhibitor was added directly to the culture 
media with 0.1% DMSO used as the solvent control 1 hour prior to virus infection.
Nucleic acid isolation, reverse transcription, PCR and Western Blot
Ten micrograms of DNase I treated RNA isolated using RNAeasy spin columns was reverse 
transcribed using ImpromII RT kit (Promega, Madison, WI) or Quantitect Reverse 
Transcription Kit (Qiagen, Hilden, Germany). Chromatin Immunoprecipitations were 
performed as previously described (Kew et al. 2014). Briefly, 106 cells were fixed and lysed 
and then subjected to sonication to shear DNA into 200-500bp fragments. DNA was then 
incubated with anti-ELK1 antibody (Cell Signaling, Danvers, MA; 1:100 dilution), anti-
phospho ELK-1 antibody (Cell Signaling, Danvers, MA; 1:100 dilution) or an isotype 
matched control (mouse IgG1; SIGMA, St Louis, MO). DNA was rescued from the IP 
complexes and amplified with MCL-1 promoter specific primers.
Gene and promoter specific primers were then used to amplify target sequences by real time 
PCR using SYBR green amplification kit (Qiagen, Hilden, Germany). MCL-1 (gene): 5’-
TGC AGG TGT GTG CTG GAG TAG and 5’-GCT CTT GGC CAC TTG CTT TTC’, 
GAPDH: 5’-GAG TCA ACG GAT TTG GTC GT and 5’-TTG ATT TTG GAG GGA TTC 
TCG, 18S: 5’- GTA ACC CGT TGA ACC CCA and 5’- CCA TCC AAT CGG TAG TAG 
CG, Bak: 5’-GCC CAG GAC ACA GAG GAG GTT TTC and 5’-AAA GTG GCC CAA 
CAG AAC CAC ACC, Bim: 5’-CAC AAA CCC CAA GTC CTC CTT and 5’-TTC AGC 
CTG CCT CAT GGA A, Puma: 5’-ACG ACC TCA ACG CAC AGT ACG and 5’-TGG 
GTA AGG GCA GGA GTC C, UL138: 5’- GAG CTG TAC GGG GAG TAC GA and 5’- 
AGC TGC ACT GGG AAG ACA CT; MCL-1 (promoter): 5′-TAG GTG CCG TGC GCA 
ACC CT and 5′-ACT GGA AGG AAG CGG AAG TGA GAA (Booy et al. 2011).
For Western Blot, 105 cells were lysed in Laemmli buffer and subjected to SDS-PAGE 
electrophoresis. Following transfer, blots were incubated with anti-MCL-1 (Cell Signaling, 
Danvers, MA; 1:500), anti-ELK-1 or anti-phospho-ELK-1 (phosphor-serine 383; Cell 
signaling, Danvers, MA; both 1:750), anti-Bak (#06-536, Millipore, Darmstadt, Germany; 
1:500), anti-PUMA (Santa Cruz, CA, 1:200) anti-actin (Abcam, Cambridge, UK; 1:1000) or 
anti-GAPDH (Abcam, Cambridge, UK; 1:2000) for 1 hour followed by detection with the 
appropriate HRP-conjugated secondary antibody. Specific bands were visualized by ECL 
detection (Amersham, Horsham, UK).
siRNA knockdown
CD34+ cells were transfected with Silencer® ELK-1 siRNAs or Silencer® negative control 
(Thermofisher, Waltham, MA) using Viromer Green transfection reagent as described by the 
manufacturer (lipocalyx/Cambridge Biosciences, UK). CD34+ cells were transfected in bulk 
in X-vivo serum free media and then plated at the required density for downstream analyses 
at 48 hours post-transfection. Prior to plating, the viromer:siRNA mix was removed from the 
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cell culture 4 hours post-transfection by pelleting the CD34+ cells at 300g followed by 
resuspension in fresh X-vivo 15 media.
Cell Death assay and Bak activation
Induction of cell death was achieved using the chemotherapeutic drug cisplatin A 
(Rosenberg et al. 1965). Cisplatin A (25uM-250uM; SIGMA-Aldrich, St Louis, MO) or 
0.1% DMSO (mock) control was added for 4 hours to trigger the apoptotic pathway. Since 
the effects of cisplatin A induced cell death are not evident until at least 12-24 hours post 
treatment (Barry et al. 1990) cell viability was performed 21 hours after cisplatin A addition. 
To determine levels of cell death, cells were stained with a TUNEL detection kit (Roche, 
Basel, Switzerland) as described by the manufacturer and analysed for apoptotic cell death 
by immune-fluorescent microscopy.
Alternatively, cell death was induced using the virus as a ligand through blockade of ERK-
MAPK signaling (U0126; 1uM, Calbiochem) 1 hour prior to infection with HCMV. 0.1% 
DMSO was used as solvent control.
Bak activation in CD34+ cells by flow cytometry was measured as previously described 
(Griffiths et al. 1999). Briefly, 105 cells were incubated with rabbit serum for 20 minutes and 
then with an anti-Bak antibody directed against the N terminal region (#06-536, Millipore, 
Darmstadt, Germany; 1:50 dilution in PBS) or an isotype matched control for 15 minutes at 
4°C. Cells were washed, incubated with goat serum for 20 minutes and then incubated with 
a goat anti-rabbit FITC conjugated secondary antibody (1:100 dilution in PBS) for 15 
minutes at 4°C. Unstained, isotype stained and Bak stained cells were then analysed by flow 
cytometry.
Assays for latent infection
CD34+ cells were infected with HCMV 48hrs post treatment with siRNAs in X-vivo-15 
media for 3 hours. Cells were pelleted, supernatant removed, washed in PBS and then re-
suspended in fresh X-vivo media and cultured for 3 days. RNA was then isolated, converted 
to cDNA and amplified in a UL138 (viral gene) and 18S (cellular gene) specific PCR. 
Changes in gene expression were calculated using 2-ΔΔCT method (UL138 and 18S RNA).
Results
HCMV infection reduces the level of activated Bak in cisplatin A treated cells
Our previous study had shown that HCMV infection could block the induction of CD34+ 
cell death in response to the chemotherapeutic drug, cisplatin A (Reeves et al. 2012). 
Cisplatin A-induced degradation of survival molecules and the triggering of cell death are 
functionally entwined events (Yang et al. 2007). Here we show that in CD34+ cells, cisplatin 
A promotes the degradation of pro-survival MCL-1, but not the related BCL-XL or Bcl-2 
proteins (Figure 1A). As expected, HCMV infection promoted MCL-1 upregulation but, 
interestingly, no effect on BCL-2 or BCL-XL was again observed (Figure 1A). A key target 
of MCL-1 is Bak. However, no impact on the total levels of Bak were observed whether 
treated with cisplatin A or infected with HCMV (Figure 1A). Similarly, no impact on the 
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transcription of Bak was detected at these early times post-infection (Figure 1B). In contrast, 
HCMV infection was a clear inducer of MCL-1 transcription (Figure 1B). We next 
investigated the activation of Bak and although levels in the total protein did not change, 
evidence of increased activation of Bak in response to cisplatin A was detected (Figure 1C). 
The specific activation of Bak can be detected by flow cytometry utilising the 
conformational change that exposes Bak epitopes when active (i.e. pro-apoptotic) Bak is 
released from the inactive complex it is normally sequestered in. As expected, resting 
CD34+ cells show very little evidence of Bak activation (Figure 1C) consistent with their 
viability status. In contrast, stimulation of CD34+ cells with cisplatin A resulted in a 
substantial increase in the level of activated Bak detectable in the cells (Figure 1C). 
Pertinently, minimal levels of active Bak were detectable in HCMV infected cells at 3hpi. 
Crucially, pre-infection with HCMV prior to cisplatin A treatment markedly reduced the 
detection of active Bak (Figure 1C) - consistent with the protective phenotype of HCMV 
against cisplatin A. Taken together, these data suggested HCMV engendered a cellular 
phenotype that was directly antagonistic to cisplatin A induced cell death.
HCMV activation of ERK-MAPK is necessary to prevent prolonged activation of Bak upon 
infection
To investigate this further we first asked whether Bak activation occurred during viral 
infection – which would underpin the need to promote a cellular environment that 
antagonises Bak activation under normal infection conditions. Intriguingly, a time course 
analysis revealed that Bak was clearly activated in infected cells at 1hpi and that, over time, 
the level of Bak activation was reversed by 3hpi (Figure 2A).
To explore this further we next exploited the knowledge that inhibition of survival pathways 
triggered by HCMV promoted the death phenotype (Reeves et al. 2012). CD34+ cells were 
pre-incubated with ERK-MAPK inhibitor for 1 hour prior to infection (Figure 2B). Cells 
were then stained for Bak activation. As expected, there was little evidence of Bak activation 
at 3hpi in infected cells or cells treated with ERK inhibitor alone. However, the infection of 
cells with inhibited ERK-MAPK signalling resulted in a clear Bak activation phenotype 
(Figure 2B) and thus clearly pheno-copied the cisplatin effect. Taken together, the data show 
that HCMV infection activates Bak which it then reverses via the concomitant activation of 
ERK-MAPK signalling.
HCMV modulates the activity of multiple Bak-interacting functions in protected cells
The activation of Bak in the mitochondrial membrane is elicited through a complicated 
interplay between effector and inhibitor mechanisms (Llambi et al. 2011). Having already 
observed changes to the levels of the MCL-1 regulator we next asked whether any impact on 
activators of Bak were triggered by HCMV. Two key pro-apoptotic molecules reported to be 
up-stream of Bak in this pathway are the pro-apoptotic PUMA and BIM BH3 proteins 
(Westphal et al. 2014). Western blot analyses indicated that basal levels of both PUMA and 
2 of 3 BIM isoforms (BimEL and BimL) were detectable in uninfected cells. Furthermore, 
HCMV infected cells analysed at 1hpi suggested that a down-regulation of both PUMA and 
BimEL was evident. In contrast no changes in BimL were detected (Figure 3A, B). We also 
noted that the highly proapoptotic isoform BimS (Marani et al. 2002) was not detectable nor 
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was expression induced upon infection. The down-regulation of both PUMA and BIMEL 
products was specific to the protein as no effect on RNA levels was observed (Figure 3C). 
Finally, the reduction in both PUMA and BIMEL levels by HCMV was dependent on ERK-
MAPK activity (Figure 3A, B).
Thus HCMV activation of ERK-MAPK was promoting several related effects that would be 
conducive for cell survival – BIM isoform and PUMA degradation alongside an up-
regulation of MCL-1 levels. MCL-1 protein levels within the cell are regulated by multiple 
processes. As well as increased transcription, MCL-1 is also regulated post-translationally 
with ERK hypothesised to promote a stabilising phosphorylation event of MCL-1 that 
antagonises degradation. Thus to investigate the potential contribution of transcription and 
translation of MCL-1 in response to HCMV, we reasoned we were required to understand 
the basis of HCMV induced up-regulation of MCL-1 mRNA expression.
Key elements responsible for the regulation of the MCL-1 promoter include binding sites for 
the ELK family of proteins (Booy et al. 2011). Western blot analysis of infected cells 
revealed that although HCMV binding did not increase the levels of ELK-1 in the cell, there 
was an apparent mobility shift which would be indicative of ELK-1 phosphorylation. This 
was confirmed using a phosphor-ELK1 specific antibody (Figure 4A). We next showed that 
the phosphorylation, and thus activation of ELK-1, was dependent on ERK-MAPK 
signalling (Figure 4B). To link this clear activation of ELK-1 upon infection with MCL-1 
expression we performed chromatin immuno-precipitation analyses. These revealed that the 
ELK1 protein was bound to the MCL-1 promoter in CD34+ cells irrespective of whether 
they were virally infected or not (Figure 4C). Although the data suggested that more ELK1 
was bound in virally infected cells, it was the analysis of phosphorylated ELK1 bound to the 
MCL-1 promoter which exhibited the clearest phenotype. Here, viral infection promoted an 
increase in the detectable levels of pELK1 at the MCL-1 promoter and this event was 
significantly dependent on ERK signalling (Figure 4C).
To test whether ELK-1 was directly involved in the pro-survival phenotype we used siRNA 
knock-down in CD34+ cells to address this. Delivery of ELK-1 siRNAs significantly 
reduced ELK-1 protein present in the cell (Figure 5A) but did not result in any overt effects 
on cell viability over the short time frame of analysis (Figure 5C). Consistent with the ChIP 
data (Figure 4C), ELK-1 knockdown in the CD34+ cells dramatically impacted on the 
ability of HCMV to up-regulate MCL-1 RNA expression (Figure 5B). Together with the 
phenotypic impact on MCL-1 gene expression, there was a clear abrogation of the virally 
induced survival response (Figure 5C). Although the delivery of ELK-1 siRNAs alone was 
not deleterious to the cell, viral infection triggered a marked increase in cell death (Figure 
5C) indicating that the elimination of ELK-1 from CD34+ cells renders them more sensitive 
to HCMV induced cell death.
ELK-1 knockout cells show elevated levels of Bak activation upon HCMV infection 
resulting in a less efficient establishment of latency
Next, we revisited our studies of Bak activation using our ELK-1 knock down cells (Figure 
6A). Unsurprisingly, ELK-1 depletion from cells had little impact on levels of Bak 
activation. However, infection of ELK-1 knock down cells again resulted in an increased 
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detection of activated Bak (Figure 6A). Although the analysis suggested that not all cells 
displayed evidence of activated Bak – which may reflect relative efficiency of siRNA knock 
down – the data clearly suggested that removal of ELK-1 from CD34+ cells promoted Bak 
activation in response to HCMV infection.
Finally, to assess if this was having any impact on the virus we assessed the ability of 
HCMV to establish latency (Figure 6B). Control or ELK-1 siRNA treated cells were 
infected with HCMV and analysed 3 days post-infection for evidence of latent viral gene 
expression. It was evident that the failure to prevent virally induced cell death manifested 
with significantly reduced levels of UL138 expression, which would be consistent with a 
failure to establish a latent infection.
Discussion
In this study we have investigated the phenotype of the pro-survival environment elicited by 
infection of CD34+ cells with HCMV. This and previous studies provide accumulating 
evidence that HCMV is required to promote an anti-apoptotic environment through the 
activation of signalling pathways in non-permissive cells in order to ensure long term 
survival (Chan et al. 2010; Peppenelli et al. 2016; Reeves et al. 2012; Stevenson et al. 2014). 
These events are likely critical for the pathogenesis and dissemination of virus in monocytes 
and the establishment of latency in CD34+ cells.
The requirement for a pro-survival signalling cascade is necessitated by the evident 
induction of prodeath responses which likely represent anti-viral responses to infection. This 
induction of pro-death responses is assumed to be due to the highly proapoptotic phenotype 
associated with viral infection when the activity of the survival factors is impaired (Chan et 
al. 2010; Reeves et al. 2012). Thus HCMV cannot necessarily completely eliminate pro-
death signalling but, instead, relies on the concomitant upregulation of survival factors to 
counter-balance this. It is of interest that a pan up-regulation of the anti-apoptotic machinery 
is not evident in the infected CD34+ cells. An analysis of 3 major players MCL-1, BCL-XL 
and BCL-2 revealed that only MCL-1 levels were affected by HCMV infection during the 
initial phases of latent infection in this cell type. However, we cannot dismiss a role for the 
other proteins completely, as the localisation or binding to target pro-apoptotic proteins of 
these other BCL-2 family members may be modified to augment the virally induced survival 
observed. Furthermore, our studies have really focussed on the role of MCL-1 as a transitory 
regulator during the very initial stages of infection. It is important to note that data from 
studies performed in the monocyte model have shown that BCL-2 activity becomes 
increasingly important to maintain the viability of the infected cells (Collins-McMillen et al. 
2015), suggesting that different molecules are required at different stages of viral infection. 
Consistent with this, reports in progenitor model systems have suggested that PEA-15 up-
regulation via the activity of interleukin-10 could play a role in long term latency in CD34+ 
cells (Poole et al. 2011, 2015; Slobedman et al. 2004). In this regard, the apparent targeting 
of the MCL-1 member of the BH3 family during the very early stages could be consistent 
with the central role that MCL-1 plays in the regulation of apoptosis in haematopoietic cells 
(Opferman et al. 2005) and also reflective of its more dynamic regulation in the cell (Adams 
& Cooper 2007). Unlike counterparts (e.g. Bcl-2, Bcl-Xl), MCL-1 has a much shorter half-
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life (Adams & Cooper 2007). Ablation of MCL-1 results in spontaneous cell death in a 
number of cell lineages, indicating that, firstly, endogenous levels of other BCL-2 proteins 
are not sufficient to compensate and secondly, it has a central role in haematopoietic cell 
survival (Dzhagalov et al. 2008; Opferman 2007; Opferman et al. 2005). This exquisite 
sensitivity of primary cells to MCL-1 levels may also involve the complex interaction of 
MCL-1 with mitochondria (Huang & Yang-Yen 2010; Perciavalle et al. 2012). As well as a 
classical role in apoptosis, MCL-1 has also been shown to regulate ATP biogenesis 
(Perciavalle et al. 2012) which we know, from studies of lytic HCMV infection, has a 
profound effect on the viability of infected cells (Reeves et al. 2007). Whether the impact of 
MCL-1 on mitochondrial bioenergetics is important here is not clear but, given the relatively 
short lived nature of the protection in the experimental conditions, it is perhaps unlikely. It is 
more plausible to have a role either in the MCL-1 mediated protection of monocytes where 
elevated MCL-1 expression persists for 72 hours (Chan et al. 2010) or, it could possibly 
augment the function of beta 2.7 during lytic HCMV infection.
Cisplatin A mediated MCL-1 degradation is a trigger for apoptosis (Yang et al. 2007) and 
thus tumours exhibiting resistance to cisplatin A often display elevated levels of MCL-1 that 
is resistant to drug induced degradation (Michels et al. 2014). It is hypothesised that the 
degradation of MCL-1 exposes Bak to the activity of pro-apoptotic proteins like PUMA and 
BIM, ultimately resulting in Bak-mediated mitochondrial dysfunction (Letai et al. 2002). 
The precise nature of the inhibitory effect of MCL-1 on Bak is debated: MCL-1 could bind 
to Bak directly to block activation or could block activation by sequestering pro-apoptotic 
BH3 proteins like PUMA and BIM or, in fact, perform both functions (Erlacher et al. 2006, 
Letai et al. 2002; Marani et al. 2002; Willis & Adams 2005).
Another possibility is that although PUMA and BIM are pro-apototic proteins themselves 
and thus viral induced degradation is a mechanism to eliminate a direct activator, another 
consequence of the down-regulation of these proteins could be contribute to increasing the 
level of ‘free’ MCL-1 in the cell. Thus the up-regulation of MCL-1 and the down-regulation 
of a binding partner that sequesters it increase the likelihood of an interaction with Bak. 
Additionally, very recent data suggests that the interaction of MCL-1 with Bak is induced 
under conditions that promote Bak oligomerisation/activation (Dai et al. 2015). Thus, viral 
infection – an apparent trigger of Bak activation – promotes a concomitant increase in 
MCL-1 levels which likely counters this. Indeed, it is interesting to note that when Bak 
activation was analysed at multiple points during the initial infection, we detected evidence 
of Bak activation at very early times which was quickly reversed.
Many of these observations were dependent on virally induced ERK-MAPK signalling. 
Viral induced activation of ERK-MAPK signalling and subsequent survival is a recurring 
theme suggesting that this pathway is a common target (Dai et al. 2016; Liu & Cohen 2013; 
Pleschka 2008; Pontes et al. 2015). The multi-factorial response driven by ERK may also 
partially explain the observation that ELK-1 activity, whilst important, was never as 
detrimental as inhibition of upstream ERK signalling. Despite this, the induction of ELK-1 
phophorylation was another virally induced response that was dependent on ERK-MAPK 
signalling. Again, this had a pro-survival effect, whereby elimination of ELK-1 
phosphorylation, and thus activation (Cruzalegui et al. 1999), either through inhibition of 
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ERK-MAPK or via a siRNA depletion of ELK-1 was deleterious, specifically upon virus 
infection. We note that evidence of ELK-1 binding to the MCL-1 promoter prior to any 
stimulation was observed and, although viral infection provided evidence of increased 
occupancy of ELK-1, phosphorylation of ELK-1 was most important for MCL-1 
transcription (Booy et al. 2011; Cruzalegui et al. 1999). The observed occupancy of ELK-1 
in an unphosphorylated (presumably inactive) form at the promoter may suggest only a 
partial involvement of ELK-1 in basal MCL-1 expression in the CD34+ cells but, instead, 
being important for dynamic responses to further stimuli. It would also be consistent with 
ELK-1 activation representing a mechanism for rapidly inducing MCL-1 expression (Booy 
et al. 2011; Vickers et al. 2004). This stimulus-specific activity would explain the virally 
induced effects on MCL-1 and, also, the transient nature of the elevated MCL-1 expression 
(Reeves et al. 2012). The virus triggers a burst of ERK-MAPK activity upon entry 
promoting ELK-1 phosphorylation but once ERK signalling is down-regulated through 
normal feedback mechanisms (Fritsche-Guenther et al. 2011) coupled with a loss of the 
initial virus binding induced signal as the virus enters the cell, then MCL-1 expression 
returns to basal levels. The occupancy of inactive or even inhibitory (e.g. p50 homodimers) 
forms of transcription factors at promoters represents a mechanism for rapid induction of 
gene expression and has been observed at multiple promoters (Altarejos & Montminy 2011; 
Baer et al. 1998; Herrera et al. 1989) including in our own studies of CREB and HCMV 
reactivation (Kew et al. 2014). Finally, although our analyses focused on the regulation of 
MCL-1 we cannot preclude the possibility that ELK-1 activates multiple responses (Boros et 
al. 2009) that contribute to survival upon viral infection. Indeed, pathogens often utilise 
central components in pathways, thus it would not be unsurprising to detect further ELK-1 
controlled responses that are important.
Prescient to this study is that ERK-MAPK signalling under certain conditions can, for 
example, be pro-apoptotic (Cagnol & Chambard 2010; Cagnol et al. 2006; Lu & Xu 2006) 
and thus in future studies it will be interesting to determine how HCMV directs the ERK 
response - possibly via the activation of concomitant pathways - to generate the pro-survival 
phenotype observed. Put simply, the kinase pathway that implements the final effector 
function (i.e. ERK-MAPK) is not dictating the outcome alone - that decision is defined by 
the nature of the signalling milieu activating the ERK-MAPK module upstream and the 
signalling and molecular context that those pathways are being activated in. Thus an aim of 
future studies is to address the identity of the death signals that are activated by the host cell 
in response to viral infection.
What this study illustrates is that viruses are the master regulators of signalling cascades and 
pathways with an impressive ability to hijack, re-direct or partition them to enhance 
infection. Understanding these events has greatly improved our understanding of cell 
biology and shed new light on the mechanisms that govern the activity of cellular functions 
required in key biological processes. Furthermore, it also illustrates how pleiotropic 
signalling pathways are modified to generate very specific outputs downstream. Greater 
understanding of these events and how they contribute to cell survival in the context of 
pathogen infection also has broader implications on our knowledge regarding the decision a 
cell makes to live or die.
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Figure 1. HCMV infection blocks cisplatin A mediated activation of Bak.
(A) Western blot analysis of CD34+ cells either mock (M), HCMV infected (V) or cisplatin 
A treated (CspA) for Bak, MCL-1, BCL-XL, Bcl-2 or GAPDH expression 2 hours post-
infection. (B) qRT-PCR analysis of RNA isolated from mock, HCMV infected or cisplatin A 
treated cells for Bak or MCL-1 expression 2 hours post-infection. Changes in gene 
expression were identified using GAPDH and 2-ΔΔCT method. n=3 (C) CD34+ cells were 
mock or HCMV infected and then incubated with DMSO or cisplatin A 3 hours post-
infection. Cells were then permeabilised and stained with an antibody that specifically 
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recognises an N terminal peptide exposed in activated Bak protein or with an isotype 
matched control. Fluorescent staining was achieved using a FITC-Goat anti-mouse antibody 
and then cells analysed by flow cytometry.
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Figure 2. HCMV infection induces a transient activation of Bak which is not reversed when ERK 
responses are inhibited.
(A) CD34+ cells were infected with HCMV and then at times 0 to 3 hours post infection 
cells were permeabilised and stained for evidence of Bak activation by flow cytometry. (B-
C) CD34+ cells were either pre-treated with an ERK inhibitor (B) or subjected to ELK1 or 
control siRNA knock-down (C) and then either mock of HCMV infected. Cells were then 
permeabilised and stained for evidence of Bak activation by flow cytometry.
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Figure 3. HCMV infection promotes down-regulation of pro-apoptotic proteins in an ERK 
dependent manner.
(A,B) Western blot analysis of CD34+ cells either mock (M), HCMV infected (HCMV) or 
HCMV infected after 1 hour of pre-incubation with and ERK-MAPK inhibitor (ERK) for 
expression of PUMA (A) or BIM isoforms. (B) protein expression was performed at 2 hours 
post-infection. GAPDH served as loading control. Densitometry was used to measure 
relative levels of protein expression (C) qRT-PCR analysis of RNA isolated from mock or 
HCMV infected cells for PUMA, BIM or MCL-1 expression was performed 2 hours post-
infection. Changes in gene expression were identified using GAPDH and 2-ΔΔCT method, 
n=3.
Kew et al. Page 19
J Mol Biochem. Author manuscript; available in PMC 2017 May 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 4. HCMV targets ELK1 for phosphorylation in an ERK dependent manner.
(A) Western blot analysis of CD34+ cells, either mock (M) or HCMV infected (V) for ELK1 
and ELK1 phosphorylation, 2 hours post-infection. Actin served as loading control. (B) 
Western blot analysis of CD34+ cells, either mock (M) or HCMV infected (HCMV) cells, 
with or without prior incubation with ERK-MAPK inhibitor (ERK) or DMSO control for 1 
hour at 2 hours post-infection. Actin served as loading control. (C) Chromatin immuno-
precipitation assays were performed on CD34+ cells with isotype (IgG), ELK1 or phosphor-
ELK1 (ELK-1p) antibodies. ChIPs were performed on CD34+ cells, HCMV infected 
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CD34+ cells or the equivalent but with prior incubation with U0126 ERK inhibitor for 1 
hour. Cells were analysed at 2 hours post infection, n=3. Students t-test was used to test for 
significance at p<0.05.
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Figure 5. Depletion of ELK1 from CD34+ cells abrogates the HCMV survival response.
(A) Western blot analysis of CD34+ cells 48 hours post-transfection with a control (Con), 
ELK1-specific (ELK) siRNA for ELK1 and GAPDH expression. (B) qRT-PCR analysis of 
RNA isolated from mock or HCMV infected cells 2 hours post-infection that have first been 
treated with either mock, control (Scr KD) or ELK1 (ELK KD) siRNAs. Changes in gene 
expression were identified using GAPDH and 2-ΔΔCT method, n=3. Students t-test was used 
to test for significance at p<0.05. (C) CD34+ cells were either mock or HCMV infected and 
then, 3 hours post-infection, incubated with cisplatin A or DMSO control. Alternatively, 
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CD34+ cells were transfected with control or ELK-1 specific siRNAs and then either mock 
or HCMV-infected. In all experiments cell viability was measured 24 hours post-infection. 
Graph is the average of 2 independent experiments analysed in triplicate.
Kew et al. Page 23
J Mol Biochem. Author manuscript; available in PMC 2017 May 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6. ELK-1 is required for the reversal of Bak activation and the establishment of HCMV 
latency.
(A,B) CD34+ cells were subjected to ELK1 or control siRNA knockdown and then either 
mock of HCMV-infected. Cells were then either permeabilised and stained for evidence of 
Bak activation by flow cytometry at 3hpi (A) or analysed 3 days post infection for evidence 
of viral latent gene expression (B).
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